On 21 September 2011 the first patient with dementia was dosed in a phase II clinical study that evaluates the efficacy of Namisol® on neuropsychiatric symptoms (NPS) in subjects with mild to moderate dementia. This study is conducted by the University Medical Center (UMC) St. Radboud under supervision of the investigator Prof. Dr. M. Olde Rikkert, as a part of a research program performed by a consortium in which UMC St. Radboud and Echo Pharmaceuticals participate. The study is expected to be completed Q2 2013.